

A retrospective study of Rhenium-SCT[®] analyses long-term data¹

Journal of Dermatological Treatment. Volume 33, 2022 - Issue 2.

Cesidio Cipriani, Maria Desantis, Gerhard Dahlhoff, Shannon D. Brown III, Thomas Wendler, Mar Olmeda, Gunilla Pietsch and Bernadette Eberlein.

Personalised irradiation therapy for NMSC by rhenium-188 skin cancer therapy: A long-term retrospective study.

Objectives

- This study aimed to provide long-term clinical data about Rhenium-SCT, an innovative epidermal radioisotope therapy, for non-melanoma skin cancer (NMSC), based on the use of the non-sealed beta emitter rhenium-188.¹

Materials and methods

- 52 NMSC patients with 55 lesions were treated. The majority of lesions were located on the head and neck region (72.73%).¹
- The treatment time was calculated by a software program. Patients' characteristics and clinical follow-up data were collected and retrospectively analysed.

Clinical outcomes

- All 55 lesions showed complete remission after 3 to 12 months of follow-up, with no complications or other post-treatment problems reported.¹

Patients and conditions¹

52 patients

55 lesions

32 basal cell carcinoma

19 squamous cell carcinoma

2 Bowen's disease

2 Extramammary Paget's disease

Average age 71.7 years

Median follow-up: 296 days¹

“A superiority of the proposed treatment with respect to surgery is evident for all tumours located in high-risk areas or difficult sites on which surgery would be difficult...”¹

Rhenium-SCT[®] uses the beta-emitting radioisotope rhenium-188 to provide targeted irradiation of NMSC tumours.¹

- Treatment involved applying a rhenium-188 paste on a plastic film onto the lesion and surrounding area, with an average treatment time of 46.35 minutes.¹
- This allowed for targeted irradiation of the tumour while sparing healthy surrounding tissue.
- Rhenium-SCT offers advantages over conventional treatments like surgery, radiation therapy, and brachytherapy, especially for elderly, infirm, or inoperable patients, and those with multiple or recurrent lesions.¹

“Rhenium-SCT is considered as an effective, rapid, safe, painless treatment mostly performed in a single therapeutic session, regardless of the shape, complexity, anatomical site and number of lesions”¹

“Published in 2022, this is the first long-term study to follow-up the outcomes of patients whose NMSCs were treated with Rhenium-SCT”¹

Examples of lesions before, during and after treatment with Rhenium-SCT®



Reprinted with permission from Cipriani C et al. 2022.¹

References: 1. Cipriani C, et al. *J Dermatol Treat.* 2022;33(2):969–975. Epub 22 Jul 2020.

Please review the Product and User information before use. This can be accessed at www.oncobeta.com
Indication: Rhenium-188 paste for the treatment of basal cell carcinoma, squamous cell carcinoma, Bowen's disease, and Erythroplasia Queyrat. OncoBeta® GmbH, Schleißheimer Str. 91, 85748 Garching near Munich, GERMANY. SHOW4280. Date of preparation: June 2024

ONCOBETA®
epidermal radioisotope therapy